Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intramuscular,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | India | Malaysia | Philippines | Taiwan | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Monash University Malaysia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Tuberculosis, Oral|Diphtheria|Tuberculosis, Cutaneous|Malaria|Lung Diseases, Fungal|Skin Diseases, Genetic|Influenza, Human|Immune Complex Diseases|HIV Infections|Skin Diseases, Bacterial|Skin Cancer|Inflammation|Skin Diseases, Infectious|Salmonella Infections, Animal|Lung Cancer|Measles|Gram-Negative Bacterial Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12624001057572 | N/A |
Not yet recruiting |
Unknown |
2025-06-30 |
|
| 21HH6540 | N/A |
Completed |
Healthy Volunteers |
2022-07-20 |
|
| BYI-0736 | P1 |
Completed |
Gram-Negative Bacterial Infections|Skin Cancer|Tuberculosis, Cutaneous|Measles|Skin Diseases, Infectious|Lung Cancer|Skin Diseases, Genetic|Skin Diseases, Bacterial|Salmonella Infections, Animal|Influenza, Human|Malaria|Immune Complex Diseases|Diphtheria|Inflammation|HIV Infections|Tuberculosis, Oral|Lung Diseases, Fungal |
2013-03-01 |